Clinical trials: Metastatic Mucosal Melanoma
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes by DEC-C during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+…
- Trial name
- NCT05089370
- Testing
- Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Melanoma
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or…
- Trial name
- MTAM (NCT04472806)
- Testing
- Toripalimab, chemotherapy in combination with Endostar
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Melanoma
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.
- Trial name
- NCT04091217
- Testing
- Atezolizumab, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
This phase I trial finds out the side effects and possible benefits of stereotactic radiosurgery and immune checkpoint inhibitors with NovoTTF-100M for the treating of melanoma that has spread to the brain (brain metastases).
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
- Trial name
- NCT05341349
- Testing
- Ipilimumab, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Metastatic, Uveal Melanoma, Metastatic
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma
- Trial name
- NCT07076550
- Testing
- [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Melanoma
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic…
- Trial name
- NCT06797297
- Testing
- IBI363, Pembrolizumab
- Where
- 31 sites in China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases).
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04511013
- Testing
- Binimetinib, Encorafenib, Ipilimumab
- Where
- 331 sites in United States
- Volunteers
- 112 people
- Sponsor
- SWOG Cancer Research Network
Melanoma (Skin)
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Trial name
- NCT00798629
- Testing
- Autologous dendritic cell-adenovirus CCL21 vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma, Mucosal Melanoma
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
- Trial name
- NCT02158520
- Testing
- Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Academic and Community Cancer Research United
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma (Skin), Melanoma Stage IV
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1…
- Conditions
- Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
- Trial name
- TIMAR1 (NCT04904120)
- Testing
- [203Pb]VMT01, [68Ga]VMT02
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Perspective Therapeutics
Metastatic Melanoma
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and…
- Trial name
- NCT00881049
- Testing
- Imatinib (Gleevec)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Metastatic Melanoma
Ipilimumab + Temozolomide in Metastatic Melanoma
The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied.
- Trial name
- NCT01119508
- Testing
- Ipilimumab, Temozolomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center